PD-L1 CPS shows encouraging potential as predictive marker for immune response to anti-PD-1/PD-L1 therapy in squamous cell carcinoma of the oesophagus, as well as in adenocarcinomas of the GEJ and stomach. Here, CD274 is linked to esophageal squamous cell carcinoma.